Clinical Governance & Safety

IVW Medical Services operates under a robust clinical governance framework, ensuring all treatments are delivered to NHS-equivalent safety standards.

Regulation

IVW Medical Services operates as a CQC-registered provider for regulated clinical activity. Our services are delivered in accordance with the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014.

Clinical Leadership

The service is delivered by NMC-registered nurses trained in intravenous therapy and immediate management of anaphylaxis, under the governance of a named medical clinical lead (GMC registered).

Safety Processes

Triage

Structured patient eligibility screening against evidence-based criteria.

Monitoring

Baseline observations and continuous monitoring throughout treatment.

Escalation

Defined emergency escalation protocols and on-site resuscitation equipment.

Audit

Rigorous incident reporting and clinical audit processes.

Quality & Outcomes

The service undertakes continuous audit of clinical activity to ensure safety and effectiveness. Key performance indicators include:

  • Clinical activity and throughput
  • Waiting times from referral to treatment
  • Adverse events and near-miss reporting
  • Patient experience and feedback
  • Referrer satisfaction

Outcome data will be published as the service develops and will be made available to commissioning partners.

Contraindications, cautions and potential adverse effects

Ferric carboxymaltose

Contraindications

Intravenous iron is not administered where any of the following are present:

  • known hypersensitivity to ferric carboxymaltose or other parenteral iron preparations
  • previous serious hypersensitivity reaction to intravenous iron
  • iron overload syndromes (e.g. haemochromatosis)
  • disturbances of iron utilisation
  • anaemia not attributable to iron deficiency
  • known hypersensitivity to any excipients within ferric carboxymaltose
  • first trimester pregnancy

Cautions

Clinical assessment is undertaken where the following are present:

  • history of multiple drug allergies
  • severe atopy, eczema or asthma
  • autoimmune disease (e.g. rheumatoid arthritis, systemic lupus erythematosus)
  • active infection
  • liver dysfunction
  • risk factors for hypophosphataemia

Treatment decisions are made based on clinical judgement and individual risk assessment.

Potential adverse effects

Patients are monitored during and after infusion in line with established protocols. Possible adverse effects include:

Immediate

  • hypersensitivity reactions
  • anaphylaxis or anaphylactoid reactions (rare)
  • infusion site reactions
  • extravasation

Delayed

  • headache
  • dizziness
  • nausea
  • flushing
  • injection site discomfort
  • transient hypophosphataemia

Serious adverse reactions are uncommon but appropriate emergency protocols are in place.